Articles related to ALLERGIES

In a stark reminder of the vulnerabilities that even healthcare professionals face, the tragic death of Dr. Kanokporn Tangsuan due to an allergic reaction at a Disney World restaurant underscores the critical importance of allergen awareness and self-care among physicians.

In a recent clinical trial, omalizumab demonstrated a significant increase in the threshold for allergic reactions to multiple food allergens in children and adolescents, suggesting its potential as a viable treatment option beyond current therapies. This study opens new avenues for the management of food allergies, providing hope for enhanced quality of life for affected individuals.

Explore this intriguing case study that highlights the importance of dietary history in diagnosing skin conditions. Gain insights into how certain foods can impact patient health.

Physicians should encourage all patients 6 months of age and older to get vaccinated against influenza this season, regardless of egg allergy. The ACIP’s updated guidance is based on the latest scientific evidence and is designed to help protect patients from influenza.

Get ready to reassess what you thought you knew about over-the-counter decongestants. Discover how patient reviews, clinical evidence, and a better understanding of these medications can transform your approach.

A phase 3, multicenter, double-blind, randomized, placebo-controlled trial was conducted to evaluate the efficacy and safety of epicutaneous immunotherapy with a peanut patch in children aged 1 to 3 years with peanut allergy. No approved treatment for peanut allergy exists for children under 4 years old. Participants with confirmed peanut allergy were assigned to either receive the peanut patch or a placebo daily for 12 months. The primary endpoint was the treatment response measured by the eliciting dose of peanut protein at 12 months. The trial showed that 67.0% of children in the intervention group demonstrated a treatment response compared to 33.5% in the placebo group. Adverse events occurred in both groups, with serious adverse events and anaphylaxis observed more frequently in the intervention group. However, serious treatment-related adverse events were rare. In conclusion, this trial demonstrated that epicutaneous immunotherapy with a peanut patch for 12 months was more effective than placebo in desensitizing children aged 1 to 3 years with peanut allergy and increasing their tolerance to peanut protein. Although adverse events were observed in both groups, serious treatment-related adverse events were uncommon. These findings suggest that epicutaneous immunotherapy may be a potential treatment option for young children with […]